Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced December 2014.

MerLion will enroll as many as 258 patients across centers in Germany and Poland for patients requiring hospitalization for urinary tract infections and pyelonephritis, positive signs for a drug in-licensed by Alcon for North America.

Australia’s Avita Medical received funding from private investors and the U.S. military for a skin culture technology treatment aimed at treating wounds and burns as well as sores developed by bed-ridden patients.

While getting ready to launch FDA-approved wound-healing product NeutroPhase in the U.S., NovaBay also has expanded a commercialization partnership with Pioneer Pharma to add 13 Southeast Asian countries and territories to a collaboration once exclusive to China.